Hydrocodone/ibuprofen - Kowa Pharmaceuticals America

Drug Profile

Hydrocodone/ibuprofen - Kowa Pharmaceuticals America

Latest Information Update: 05 Aug 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProEthic Pharmaceuticals
  • Developer Kowa Pharmaceuticals America
  • Class Morphine derivatives; Nonsteroidal anti-inflammatories; Opioid analgesics; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Acute pain

Most Recent Events

  • 04 Aug 2008 ProEthic Pharmaceuticals has been acquired by Kowa
  • 14 Mar 2008 Launched for Acute pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top